• Teva Pharmaceutical Industries Ltd TEVA.N reported quarterly adjusted earnings of 71 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $1.00. The mean expectation of six analysts for the quarter was for earnings of 70 cents per share. Wall Street expected results to range from 67 cents to 75 cents per share.

• Revenue fell 5.1% to $4.23 billion from a year ago; analysts expected $4.13 billion.

• Teva Pharmaceutical Industries Ltd's reported EPS for the quarter was a loss of 19 cents​.

• The company reported a quarterly loss of $217 million.

• Teva Pharmaceutical Industries Ltd shares had fallen by 2.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.3% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Teva Pharmaceutical Industries Ltd is $26.00

This summary was machine generated from LSEG data January 29 at 01:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)